case_images: PMC7098338_01
case_images: Clinical courses of ADPKD patients who received tolvaptan therapy. A Case 1. B Case 2. Solid line: estimated glomerular filtration rate (eGFR); gray bar: total kidney volume.
case_images: cnd-0010-0009-g01.jpg
case_images: PMC7098338_02_cnd-0010-0009-g01.jpg
case_images: F1
case_images: TKV determined with an ellipsoid equation increased from 1,290 mL before starting tolvaptan treatment to 2,570 mL at the most recent examination, for an annual rate of increase of 11.0% (Fig. 1B). TKV in case 2 showed a gradual increase, from 4.7% per year in the initial 3-year period to 12.5 % per year in the most recent 6-year period.
case_images: PMC7098338_02
case_images: Clinical courses of ADPKD patients who received tolvaptan therapy. A Case 1. B Case 2. Solid line: estimated glomerular filtration rate (eGFR); gray bar: total kidney volume.
case_images: cnd-0010-0009-g01.jpg
case_images: PMC7098338_02_cnd-0010-0009-g01.jpg
case_images: F1
case_images: TKV determined with an ellipsoid equation increased from 1,290 mL before starting tolvaptan treatment to 2,570 mL at the most recent examination, for an annual rate of increase of 11.0% (Fig. 1B). TKV in case 2 showed a gradual increase, from 4.7% per year in the initial 3-year period to 12.5 % per year in the most recent 6-year period.